Beta: Podcast at the ZEV show

 

Dense Breast Disclosure Act- Speech (LG)

Teaster- Schwartzbard

Legacy Story: SchwartzBARD

AYD

 

High-Frequency Ultrasound Examination of Melanoma and Skin Cancer

Written by: Dr. Robert Bard - Article updated 8/21/2024

Today’s health conscious society means adults routinely seek reassurance about suspicious skin lesions. Diagnostic ultrasound examinations can accurately and rapidly differentiate between epidermal, dermal, and subcutaneous tissues in real time. This procedure may help to identify lesions invisible to the spatially restricted human eye. The high resolution and low cost of today’s ultrasonographic equipment allow this modality to be used readily in an outpatient office setting.

The accuracy of ultrasonography in the epidermis, dermis, and subcutaneous tissues is both operator and equipment dependent. Standard 2-dimensional linear sonograms at 40 to 100 MHz image the epidermis. Probes using 15-to 22-MHz image the epidermis and dermis, including the adjacent tissues 1 to 2 cm deep to the basal dermal layer. Real time 3-dimensional (3D/4D) probes at 16 to 20 MHz using broadband technologies provide high resolution of these structures to a 4- to 7-cm depth in seconds. Today’s high-resolution equipment is a widely available imaging technology.

MELANOMA
Malignant melanoma, one of the most lethal cancers, is increasing at an alarming rate. It is the leading cause of death in women aged 20-43 years. Importantly, only 1 out of 33,000 moles are malignant and sonography may prevent unnecessary biopsies. The chance of aggression is related to the tumor depth. Tumors less than 1 mm are often cured by biopsy. Disease greater in penetration is readily imaged by 3D Volumetric probes and non-palpable foci of tumor extension or lymph node (glands) involvement are visible in the scanned area. The metastatic potential is measured by the 3D Doppler study and follow up of distant tumor spread may be correlated with serial sonography. Some invasive surgical diagnostic procedures may be avoided by using high resolution imaging since scans detect tumor nests as small as 2 mm in the lymph nodes. This means that a sonogram guided needle biopsy may avoid the necessity of a massive radical operative dissection of otherwise healthy tissues.

DIAGNOSTIC APPLICATIONS FOR NON-MELANOMA SKIN CANCER: Clinical diagnosis is the primary modality used to identify nonmelanoma skin cancer; however, visual diagnosis alone cannot determine tumor depth. Imaging allows preoperative mapping of a lesion, which may alert the surgeon to the depth or subcutaneous extension of a lesion. This information allows surgical planning, which helps to limit the number of stages required and allow for preoperative planning to identify optimal techniques for surgical closure. The presence of coexisting benign disease, such as seborrheic hyperplasia or peritumor inflammatory reaction may falsely lead to a wider excision or inaccurate biopsy conclusions. Of basal cell carcinomas, 85% develop in the head and neck, showing a predilection for thin skin, such as the nose, lips, or eyelids. The various shaped probe constructions allow diagnostic evaluation of nearly all locations including external ear compartments (Fig. 2). Although most basal cell carcinomas lesions appear as well-defined, oval, echo-poor masses, lesions that may have a higher aggressive potential may also appear as hyperechoic spots.

Fig. 1. Basal cell carcinoma echo-poor lesion (circle) 2.1 mm deep located 5 mm from the facial nerve (arrows) and 7 mm from temporal vein (blue).







Fig. 2. Basal cell carcinoma (red circle) echo-poor mass in nasolabial groove imaged with small transducer to improve contact depth measurement of 1.5 mm.  





Identification of these foci is useful because malignant neovascularity is less than that in other cancers. Indeed, the appearance of tortuous vessels suggests squamous cell carcinoma, Merkel cell carcinoma or metastatic tumor. The depth correlation between ultrasonography and histology is excellent, 5 which allows for better preoperative planning. (figure 3)


Fig. 3. Basal cell carcinoma echo-poor mass with involvement of the orbicularis oculus muscle (m). Tumor (asterisk) echogenic foci signifies increased aggression and invades the dermis (d) and muscle layer (m) into the fat (arrow).



Squamous cell carcinoma presents as a hypoechoic lesion with irregular borders. Because the thickness or depth of invasion is an important predictor of metastases, the lesion should be followed along its entire course. Extra care is taken to find locoregional metastases and ultrasound examination of the liver and regional nodes may be performed simultaneously. The vascular pattern is increased diffusely throughout the entire mass as opposed to basal cell carcinomas, where the neovascularity is less prominent and often at the bottom of the lesion. Vascular mapping for major feeders with 3D ultrasonography is useful owing to the possibility of widespread penetration of the lesion.

TechReview: Exploring the DermaSensor™ - Until recently, the approach of identifying skin cancers was commonly a visual self-exam or a clinical exam conducted by a health care provider and/or a dermatologist.  A skin biopsy is the only way to definitively diagnose skin cancer- where a small sample of the suspicious skin is removed and sent to a lab for examination (under a microscope) in search of cancer cells.  HEALTHTECH REPORTER is proud to introduce another non-invasive advancement in skin cancer diagnostics. DermaSensor™ is an AI powered, FDA-cleared innovation designed to help physicians detect skin cancer at the point of care. According to a recent DEMO DAY @ Bard Diagnostics in NYC, clinical educators provided a comprehensive tour of what appears to be a ground-breaking innovation for primary care physicians "offering actionable results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically".  DermaSensor™ was designed as a portable and fast-access noninvasive point-of-care assessment tool for primary care physicians to offer additional information about a lesion to aid in their consideration of a referral decision. (DermaSensor™ does not definitively determine whether or not cancer is present, specify what type of cancer may be present, or make any decision for the user.) (See complete feature)

EVOLUTION OF DIAGNOSTIC ULTRASOUND IMAGING: Diagnostic ultrasound examination has been used on the skin and subcutaneous tissues for more than 25 years in Europe and Japan. The technology has evolved from its original use in cyst detection with 2D scans to its present use for cancer detection using 3D imaging to detect in-transit metastases. Additionally, in vivo flow velocity analysis now detects melanoma vessel density and analyzes tumor microvascularity with ultrahigh resolution. Experimental photo and laser acoustic technologies are currently being studied in animal research. This article provides a basic overview of skin imaging applications. A more in-depth review of dermal ultrasonography may be found elsewhere in the literature.

HOW THE EXAMINATION IS PERFORMED: The application of ultrasonography depends on the area examined and equipment needed for specific diagnosis. All probes require gel contact with the skin and scan duration is typically proportional to the type of probe and examiner’s experience. Real-time imaging by a trained physician allows simultaneous picture generation and interpretation to occur within minutes. Routine 2D scan units require operator-dependent probe motion in 2 planes to obtain orthogonal images. The 3D imaging systems are operator independent because the probe is held steady over the area of interest and electronics scan a 4x4 cm area in 6 seconds. Patient motion rarely degrades the images owing to the rapid scan rate. Transducer size is matched to scan areas or can be focused to limited facial regions such as the nose. Three-dimensional imaging of ear and nose cartilage is also available with specialized probes. Lesions can be echogenic or hyperechoic (many internal echoes), such as hemorrhagic areas, echo poor or hypoechoic (few internal echoes), and echo free (no internal echoes), which are usually found in fluid, such as cysts.


ULTRASOUND EVALUATION OF DERMAL LESIONS: The incidence of melanoma and nonmelanoma skin cancer are both increasing. Earlier detection discovers smaller lesions where focal nonsurgical treatment may be preferred to standard operative techniques, which may limit potential long-term and postoperative side effects. Ultrasound examination permits rapid measurement of skin thickness, fat tissue depth, and fascial integrity. Medical imaging maps arteries, veins, and nerves  providing preoperative landmarks reducing the risk of postoperative bleeding and nerve damage (Fig. 1). Image-guided treatment may also decrease the risk of postoperative disfigurement. Interval scans may also be used to track and assess lesions with low aggressive potential.

...................................................................................................................................................................

About the Author:

Robert L. Bard, MD, DABR, FAIUM, FASLMS is internationally known and recognized as a leader in the field of 21st Century 3-D ULTRASONOGRAPHIC VOLUMETRIC DOPPLER IMAGING. Dr. Bard specializes in advanced 3-D sonography to detect cancers in numerous organs including the breast, prostate, skin, thyroid, melanoma and other areas. Dr. Bard’s images are used to accurately guide biopsies, target therapy and provide focused follow-up after treatment.

As of Jan '18, Dr. Robert Bard spearheaded a partnership with a host of cancer educators, medical practitioners and non-profit foundations (allied under AwarenessforaCure.org) to form a public resource program to aid in the advancement of the public's understanding about self-preservation from cancer and other chronic diseases. EARLY DETECTION & PREVENTION is a global health movement that promotes a higher regard for "clean living" - from toxins and a toxic lifestyle. Our program consists of four main efforts: EDUCATION, COMMUNITY CONNECTION, CURRENT NEWS & CLINICAL RESOURCES. EARLY DETECTION & PREVENTION brings the empowerment of wellness through group seminars, videos and the distribution of current articles & newsletters published/shared to all the major cancer charities and their members.

For more information or to subscribe to our EARLY CANCER DETECTION & PREVENTION PROGRAM newsletter, contact Bard Cancer Diagnostics today at: 212.355.7017 (www.BardCancerDiagnostics.com)- or email us at: bardcancercenter1@gmail.com


Disclaimer & Copyright Notice: The materials provided on this website/web-based article are copyrighted and the intellectual property of the publishers/producers (The NY Cancer Resource Alliance/IntermediaWorx inc. and Bard Diagnostic Research & Educational Programs). It is provided publicly strictly for informational purposes within non-commercial use and not for purposes of resale, distribution, public display or performance. Unless otherwise indicated on this web based page, sharing, re-posting, re-publishing of this work is strictly prohibited without due permission from the publishers.  Also, certain content may be licensed from third-parties. The licenses for some of this Content may contain additional terms. When such Content licenses contain additional terms, we will make these terms available to you on those pages (which his incorporated herein by reference).The publishers/producers of this site and its contents such as videos, graphics, text, and other materials published are not intended to be a substitute for professional medical advice, diagnosis, or treatment. For any questions you may have regarding a medical condition, please always seek the advice of your physician or a qualified health provider. Do not postpone or disregard any professional medical advice over something you may have seen or read on this website. If you think you may have a medical emergency, call your doctor or 9-1-1 immediately.  This website does not support, endorse or recommend any specific products, tests, physicians, procedures, treatment opinions or other information that may be mentioned on this site. Referencing any content or information seen or published in this website or shared by other visitors of this website is solely at your own risk. The publishers/producers of this Internet web site reserves the right, at its sole discretion, to modify, disable access to, or discontinue, temporarily or permanently, all or any part of this Internet web site or any information contained thereon without liability or notice to you.

Process Report 1: Dr. H. Blatman on the progress of the VSELs Laser Guided Procedure

 

KINESIOLOGICAL ANALYSIS:  VSELs TREATMENT PROGRESS EXPLAINED

By:  Matthew Einsohn, ND

This might seem like a small thing, but it's actually a big deal. When you're sitting, lifting your leg involves working against gravity, which is already challenging. But when you're lying down, it requires a whole different set of muscles and coordination. It means engaging not just the hip flexors but also the core and stabilizing muscles of the lower back and pelvis. This shows his overall muscle function and coordination have significantly improved.

Without the help of gravity, his core muscles have to work even harder to stabilize and support the movement. This improvement in core strength is great news. Plus, this movement indicates improved flexibility and range of motion, likely due to decreased muscle stiffness and better neuromuscular control.

Being able to perform this movement both sitting and lying down means his nervous system and muscles are working together more effectively. This is crucial for overall mobility and daily activities.

When Dr. Blatman is discussing the origins of pain, which is associated with sheer force and pressure, it appears that stabilization has been achieved. Based on watching the video a couple times, I would theorize that significant restoration is occurring. It seems he has addressed the root cause of the pain by restoring the integrity of the fascia.

Additionally, while there is a notion that one can make injuries less noticeable, this approach does not seem to align with his method. Instead, if he is indeed focusing on restoring the integrity of the fascia, it suggests that he is addressing the fundamental issue underlying the pain rather than merely masking the symptoms.

Some conditions just this mechanism can help with:

* Muscle weakness and atrophy from post-stroke rehabilitation or muscle degenerative diseases

* Neurological disorders such as MS or Parkinson's

* Recovery from spinal injuries

* Any chronic pain such as Fibromyalgia

* Anyone with joint or mobility problems

Muscle Weakness and Atrophy: Conditions causing muscle weakness or atrophy, such as post-stroke rehabilitation or muscle degenerative diseases, might see improvements in strength and coordination with similar treatments.

Neurological Disorders: Disorders like multiple sclerosis or Parkinson's disease, where muscle control and coordination are affected, could benefit from enhanced muscle function and coordination.

Post-Surgical Rehabilitation: Recovery from surgeries, especially orthopedic or spinal surgeries, could be supported by treatments that improve muscle strength, flexibility, and functional movement.

Chronic Pain Conditions: Conditions like fibromyalgia or chronic back pain that involve muscular and structural issues might see relief through better muscle engagement and reduced stiffness.

Balance and Stability Issues: Treatments that enhance core strength and overall muscle coordination can help with balance and stability, which is crucial for individuals with vertigo or balance disorders.

Joint and Mobility Problems: For conditions like arthritis or other joint issues, improving range of motion and muscle strength can reduce pain and enhance mobility.

Sports Injuries: Athletes recovering from injuries might benefit from improved muscle function and coordination, aiding in a quicker and more effective recovery.

MEET DR MATTHEW EINSOHN: NEW HOST FOR HEALTHTECH REPORTER

 

Women's Health Collaborataive: Earlier Detection - w/ guest advocate Sen. Patricia Canzoneri-Fitzpatrick

 FOR INTERNAL USE ONLY: DO NOT POST OR SHARE

VIDEO SPOTLIGHT: Cancer Science News features Dr. Ben Ho Park on EARLIER DETECTION & THE TYPES OF BREAST CANCERS Ben Ho Park, MD, PhD, is Director of the Vanderbilt-Ingram Cancer Center (VICC). Dr. Park is also a Professor of Medicine in the Department of Medicine's Division of Hematology and Oncology. Dr. Park's research is dedicated to finding a cure for all types of breast cancer by investigating mutated and altered genes responsible for the development and progression of breast cancer, as well as genes that lead to drug resistance. He is actively involved with the VICC Breast Cancer Research Program’s clinical research team to translate his research into clinical practice and patient care.  (Complete interview & feature story)

Heart Rate Variability (Demo)

 

Active Surveillance: The Jim Hunt Story (part 1)

 

DON'T BE SO QUICK TO DO SURGERY!

Fact: Regular screenings and early detection tests are the best and most proactive way to staying on top of your health.  Should these exams uncover a cancer growth, physicians would undergo specific considerations depending on the patient's diagnosis.  If the cancer is "low grade" or too small in size/volume (less than 5mm), ACTIVE SURVEILLANCE is often the recommended step over any interventional procedure.  

ACTIVE SURVEILLANCE DEFINED: Closely watching a patient’s condition but not giving any treatment unless there are changes in test results that show the condition is getting worse. Active surveillance may be used to avoid or delay the need for treatments such as radiation therapy or surgery, which can cause side effects or other problems. During active surveillance, certain exams and tests, such as blood tests, imaging tests, and biopsies, are done on a regular schedule to monitor the condition. Active surveillance may be used in certain types of prostate cancer and in some other types of cancer. It is a type of expectant management.

According to NYC cancer radiologist Dr. Robert Bard, "prostate cancer is extraordinarily common as you grow older. So the question is, how deadly is it?  According to the highly referenced textbook "Ewing's Sarcoma", active prostate cancer is extraordinarily rare in the prostates. But as we grow older and we start biopsying things, we find cancer- but a lot of it is low grade cancer- and evidently,  the body fights it off naturally.  It's abnormal, it's invasive but the body is strong enough to counteract it. So the question is not "do you have prostate cancer in your 50's?", but "will it kill you or will you die with it?"

Active surveillance is a logical next step for anyone with Low-Risk or low-grade Prostate Cancer.  Today's diagnostic community actually has the proper technology that shows what it is, where it is, and how aggressive it is.  You can follow your tumor aggression as we have been able to do for the last 30 years.

Through clinical imaging, we follow tumor aggression.  We use the same tracking solutions to monitor treatment efficacy or recurrence.  In Jim's case, active surveillance allowed us to constantly monitor for  any abnormalities beyond the status of a low-grade tumor.   Within 6+ years of monitoring, we saw very little activity to NOT jump into any clinical procedure.  He had time to research on what's available out there, while maintaining his health to keep his tumor controlled. 

Aside from regular scanning with 3D Doppler Ultrasound, he also received MRI scans as part of his monitoring program. The MRI is important because it shows if this cancer has broken out of the prostate and into the bones, because that's something you can't feel when it's metastasized through the body. In his case, it stayed localized and intact within the capsule.  We can see this better on the 3D Doppler ultrasound, then with MRI. 

HEALTHTECH REPORT: Dr. Matt Einsohn shares his new findings about AVACEN health effects

 

Jim Hunt- Proton Center

 

First Responders Health News: Feat. Chief R. Osgood on Dermal Screening with FCRN & AAD

 

DR HAAS

 

DAVID WEST & MANAGING SPORTS PAIN

 

Dr. Bard Explores Laser-Guided VSEL Therapy in Post-Polio Viral Solution (Part 1)

FOR INTERNAL USE ONLY: DO NOT SHARE OR POST

VSELs by definition are Very Small Embryonic-Like Stem cells.  They are rare stem cells found in adult tissues that may have potential in regenerative medicine. They are slightly smaller than red blood cells and are located in the inner cell mass of the blastocyst during early development. VSELs are quiescent but can be activated during stress and mobilized into peripheral blood. They have a distinct morphology with a high nuclear/cytoplasmic ratio and undifferentiated chromatin. VSELs also express markers of pluripotent stem cells, such as Oct4, Nanog, and SSEA, and markers of primordial germ cells (PGCs), which suggests they may be related to PGCs. 

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461217/

PROCEDURE REPORT:

DR. BLATMAN'S TRANSCRIPT ON DR. BARD'S VSELs TREATMENT DAY 1

Dr. Bard and I started the procedure with a deep discussion, making sure we had his wishlist and an understanding of what he was specifically wanting and trying to get better. By the time we proceeded, we drew eight tubes of blood, we spun it down, and concentrated his plasma. And then we lasered that plasma and prepared the VSELs out of the solution, activating dormant, very small embryonic like stem cells from his blood -dormant since his birth. And then we prepared them for injection into him. We used eight syringes of these VSELs to inject specific parts of him. There were tendons anchoring his right quadriceps. There were tendons anchoring both of his butt muscles. There were muscles and tendons anchoring the end of his quadriceps that help him control his knee whose weakness brings him knee pain.

I believe he was able to tell that when we were doing that needle surgery to put the VSELs to facilitate repair of all those fascia anchors, he could tell that the needle was in the right spot. Because you can tell when you're, when, when you've experienced this for so long and you can feel what's going on inside your body, you have a way of knowing that I'm in the right spot. And then after we finished that part of the procedure, we used the nitrous oxide because it was quite uncomfortable and he was able to breathe.  This made it a whole lot less uncomfortable for him. And we followed that with giving him a little more than 40 CCs. He also took that intravenously with an ozone IV at the same time. So the “babies were piggybacked” into the ozonated blood IV after his blood went through ultraviolet light to clean it. As these cells were going into his body, we used the laser to guide these cells to where we want them to get stuck and where we want them to help. And so we sent these to his brain, to his cerebellum and balance centers down his spinal cord and then into his right thigh.

I'm hoping to see if we could reactivate some of the nerves that were damaged from the polio, because when polio damages nerves, it doesn't interrupt. They're still there, they just don't work. So we're hoping that they're still there enough that we can coax them to work or coax them to health. And we don't know if there's a chance to do that or not, because to the best of my knowledge, this has never been done before (with Post-Polio syndrome). So we are the first ones I would think, to use VSELs in polio for the regeneration of the nervous system and to see if it would work.

When we inject into joints, you can see the cartilage vertical dimension increase. When you inject into rotator cuff tendon, you can subsequently see with ultrasound that the tendon defect filled in. You can also see it on MRI that the defect in the tendon filled in.

We have some patients with Parkinson's in the treatment group from this laser that have shown improvement in 30 minutes. So it can happen pretty quickly. It can also take two or three months before you see a change. You never know.

SCAN AND TREAT 2: PBMT

 

SCAN AND TREAT: IMAGE GUIDED TREATMENT OF PEMF ON ENLARGED PROSTATE: BY DR. ROBERT BARD

 

Zoom w/ the Women's Health Initiative and the office of Congressman D.Esposito